Due to the COVID-19 pandemic, the global Compound Ammonium Glycyrrhetate S for Injection market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Compound Ammonium Glycyrrhetate S for Injection market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Compound Ammonium Glycyrrhetate S for Injection landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
40mg/Piece (Calculated As Monoammonium Glycyrrhizinate S) accounting for % of the Compound Ammonium Glycyrrhetate S for Injection global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Compound Ammonium Glycyrrhetate S for Injection include Shanxi PUDE Pharmaceutical, Dezhou Deyao Pharmaceutical, Shandong Wego Pharmaceutical, Jilin Century Hanke Pharmaceutical, Qingdao Jinfeng Pharmaceutical, Jilin Connell Pharmaceutical, Dalian Tianyu Pharmaceutical, Hainan Weikang Pharmaceutical and Shaanxi Jingxi Pharmaceutical, etc. In terms of revenue, the global 3 largest players have a % market share of Compound Ammonium Glycyrrhetate S for Injection in 2021.
This report focuses on Compound Ammonium Glycyrrhetate S for Injection volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Compound Ammonium Glycyrrhetate S for Injection market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America and China., etc.
Global Compound Ammonium Glycyrrhetate S for Injection Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Specification and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Specification
40mg/Piece (Calculated As Monoammonium Glycyrrhizinate S)
80mg/Piece (Calculated As Monoammonium Glycyrrhizinate S)
120mg/Piece (Calculated As Monoammonium Glycyrrhizinate S)
160mg/Piece (Calculated As Monoammonium Glycyrrhizinate S)
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Shanxi PUDE Pharmaceutical
Dezhou Deyao Pharmaceutical
Shandong Wego Pharmaceutical
Jilin Century Hanke Pharmaceutical
Qingdao Jinfeng Pharmaceutical
Jilin Connell Pharmaceutical
Dalian Tianyu Pharmaceutical
Hainan Weikang Pharmaceutical
Shaanxi Jingxi Pharmaceutical
Hubei Kangqin Pharmaceutical
Hubei Noon Pharmaceutical
Xi'an Disai Biopharmaceutical
AdvaCare